Abstract
In the last years, new systemic and locoregional therapeutic schemes have been developed for the management of liver secondaries due to neuroendocrine character tumors. Among the novel therapeutic procedures, intra-arterial infusions of high doses of 111In-Octreotide were leading to encouraging results covering the whole spectrum of liver metastases both in early and in advanced cases. The transhepatic radiopeptide infusions to confront liver metastases could be in fact an increasingly used form of “brachytherapy” which consists of the intra-arterially injection of octreotide tagged with 111In, a gamma, Auger, and internal conversion electron emitter with a 2.8-day half-life and an average 0.02–550μm tissue penetration, acting as a source of endovascular radiation purposes.
In this chapter, it is aimed to evaluate the efficiency of the outcome and toxicity of peptide-receptor-radionuclide therapy (PRRT) in patients with liver-metastasized neuroendocrine tumor positive for somatostatin receptors due to surgically excised colorectal carcinoma, using 111In-Octreotide, in high doses, discussing and analyzing the recent ergography developments on the field.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bogacka B, Marlicz W, Białek A, et al. Trends in colorectal neuroendocrine tumors: a 10 years review. Gut. 2009;58:A296.
Ramage JK, De Herder WW, Delle Fave G, et al. Vienna Consensus Conference participants. ENETS consensus guidelines update for colorectal neuroendocrine neoplasms. Neuroendocrinology. 2016;103(2):139–43.
Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934–59.
Modlin I, Kidd M, Latich I, et al. Current status of gastrointestinal carcinoids. Gastroenterology. 2005;128:1717–51.
Rydzewska G, Cichocki A, Ćwikła JB, et al. Gastroduodenal neuro-endocrine neoplasms including gastrinoma—management guidelines (recommended by the Polish Network of Neuroendocrine Tumours). Endokrynol Pol. 2013;64(6):444–58.
Maggard MA, O’Connell JB, Ko CY. Updated population-based review of carcinoid tumours. Ann Surg. 2004;240:117–22.
Matsui K, Iwase T, Kitagawa M. Small, polypoid-appearing carcinoid tumors of the rectum: clinicopathologic study of 16 cases and effectiveness of endoscopic treatment. Am J Gastroenterol. 1993;88:1949–53.
Caplin M, Sundin A, Nillson O, et al. ENETS Consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms. Neuroendocrinology. 2012;95:88–97.
Anthony LB, Strosberg JR, Klimstra DS, et al. The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (nets): well-differentiated nets of the distal colon and rectum. Pancreas. 2010;39:767–74.
Limouris GS, Chatziioannou A, Kontogeorgakos D, et al. Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuro-endocrine liver metastases. Eur J Nucl Med Mol Imaging. 2008;35:1827–37.
Kobayashi K, Katsumata T, Yoshizawa S, et al. Indications of endoscopic polypectomy for rectal carcinoid tumors and clinical usefulness of endoscopic ultrasonography. Dis Colon Rectum. 2005;48:285–91.
Kwekkeboom DJ, de Herder WW, van Eijck CHJ, et al. Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med. 2010;40(2):78–88.
Lung MS, Hofman M, Kong G. Outcomes of peptide receptor radionuclide therapy (PRRT) in metastatic grade 3 neuroendocrine tumors (NETs). J Clin Oncol. 2017;2017:35. (15 suppl. Abstract e15694).
Garske-Román U, Sandström M, Fröss-Baron K, et al. Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity. Eur J Nucl Med Mol Imaging. 2018;45:970–88.
Kong G, Grozinsky-Glasberg S, Hofman MS, et al. Highly favorable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN). Eur J Nucl Med Mol Imaging. 2019;46(3):718–27.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Limouris, G.S., Zafeirakis, A.G. (2021). 111In-Octreotide Infusions for the Treatment of Colorectal Carcinoma. In: Limouris, G.S. (eds) Liver Intra-arterial PRRT with 111In-Octreotide. Springer, Cham. https://doi.org/10.1007/978-3-030-70773-6_15
Download citation
DOI: https://doi.org/10.1007/978-3-030-70773-6_15
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-70772-9
Online ISBN: 978-3-030-70773-6
eBook Packages: MedicineMedicine (R0)